Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

1.1K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
1.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Current <i>in vitro</i> myocardial infarction co-culture models and their verification for clinical relevance.

Expert reviews in molecular medicine·2026
Same author

In vitro cardiac new approach methodologies predict clinical cardiovascular repolarization risk comparable to non-clinical animal studies.

British journal of pharmacology·2026
Same author

Drug Proarrhythmic Evaluation in a High Throughput Cardiac New Approach Methodology.

bioRxiv : the preprint server for biology·2026
Same author

Dental, Oral and Craniofacial Tissue Regeneration Consortium (DOCTRC): An infrastructure for accelerating regenerative therapies from discovery to clinical impact.

Journal of clinical and translational science·2026
Same author

Nonclinical human neural new approach methodologies (NAMs): Electrophysiological assessment of opioid agonist and antagonist combination.

NAM journal·2026
Same author

Repairing Volumetric Muscle Loss with Skeletal Muscle Units and Hyaluronic Acid Hydrogel in Rats.

Tissue engineering. Part A·2025

相关实验视频

Updated: Sep 10, 2025

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.2K

非临床人类心脏新方法 (NAMs) 预测瓦诺谢林诱导的前节律潜力

M Iveth Garcia1, Bhavya Bhardwaj1, Keri Dame1

  • 1Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.

Journal of cardiovascular development and disease
|August 27, 2025
PubMed
概括

新方法方法 (NAM) 准确预测瓦诺谢林

关键词:
处理心肌细胞复杂的体外模型收缩性电生理学这里是 hiPSC CM微生理系统 (MPS)新方法方法 (NAM)非临床研究

更多相关视频

Optocardiography and Electrophysiology Studies of Ex Vivo Langendorff-perfused Hearts
09:52

Optocardiography and Electrophysiology Studies of Ex Vivo Langendorff-perfused Hearts

Published on: November 7, 2019

13.1K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

相关实验视频

Last Updated: Sep 10, 2025

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.2K
Optocardiography and Electrophysiology Studies of Ex Vivo Langendorff-perfused Hearts
09:52

Optocardiography and Electrophysiology Studies of Ex Vivo Langendorff-perfused Hearts

Published on: November 7, 2019

13.1K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

科学领域:

  • 心血管毒理学
  • 在体外药理学
  • 干细胞生物学

背景情况:

  • 瓦诺谢林在临床试验中引起心脏事件,但在早期的非临床研究中没有.
  • 新方法 (NAM) 提供了先进的体外模型来评估药物安全性.
  • 心脏微生理系统 (MPS) 和人类诱导的多能干细胞衍生的心肌细胞 (hiPSC-CM) 提供了与人类相关的数据.

研究的目的:

  • 使用人类心脏NAM来评估瓦诺谢林对心脏的影响.
  • 评估心脏NAM对临床结果的预测能力.
  • 调查瓦诺谢林引起的心脏激发-收缩的变化.

主要方法:

  • 使用心脏MPS与hiPSC-CMs测量电压,处理和收缩性.
  • 使用多电极阵列 (MEAs) 的hiPSC-CM综合体内心律失常试验 (CiPA).
  • 评估了瓦诺谢林对心脏功能和复极化的度依赖性影响.

主要成果:

  • 在两种NAM平台中,瓦诺谢林延迟了复极化并诱导了前节律事件.
  • 心脏MPS显示频率依赖的效应,EADs在1.5Hz节拍时被消除.
  • 暴露分析表明心脏MPS中存在显著的瓦诺谢林损失.
  • 在临床度下,TdP风险分析表明高至中等风险.

结论:

  • 心脏NAM成功地回顾了瓦诺谢林的临床结果.
  • 这些模型检测到瓦诺谢林诱导的延迟复极化和前节律失常.
  • 这项研究支持评估药物安全性和减少动物试验的NAM.